Laboratoires Juvisé Pharmaceuticals

Privately held: no public share price · France

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
AromataseSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
S1P receptorSmall molecule
Inflammatory Bowel DiseasePsoriasisMultiple Sclerosis
Ulcerative Colitis

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
August 2028 (1)
PonesimodPhase 3Moderate-to-severe Chronic Plaque Psoriasis
Est. primary completion 2028-08 · NCT07362017 · CT.gov ↗
What to watch
2029 (2)
April 2029 (1)
PonesimodPhase 3Ulcerative Colitis (UC)
Est. primary completion 2029-04 · NCT07686081 · CT.gov ↗
What to watch
December 2029 (1)
AnastrozolePhase 3Advanced Breast Cancer
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.